C

Cooper Companies Inc
NASDAQ:COO

Watchlist Manager
Cooper Companies Inc
NASDAQ:COO
Watchlist
Price: 71.21 USD -0.35% Market Closed
Market Cap: $13.9B

Cooper Companies Inc
Investor Relations

In the world of healthcare innovation, Cooper Companies Inc. etched its name as a significant player, specializing in creating products that enhance lives, particularly in the fields of vision care and women’s health. Established in 1958, Cooper Companies evolved to become a holding company operating through its two primary business units: CooperVision and CooperSurgical. CooperVision is renowned globally for its expertise in contact lenses, providing a diversified range of lenses to correct myopia, hyperopia, astigmatism, and presbyopia. By leveraging cutting-edge technology and a deep understanding of wearer needs, CooperVision caters to a wide spectrum of users, from daily disposables to specialty lenses, thus driving consistent revenue through the consumable nature of its products.

CooperSurgical, on the other hand, focuses on solutions for women’s health, offering a gamut of medical instruments, devices, and diagnostics. This unit extends Cooper Companies' footprint into the realms of fertility products, contraception, and obstetrics. By addressing key segments of the women’s health market, CooperSurgical supports clinical needs across a woman’s lifespan. Revenue opportunities here arise from both its durable medical equipment and consumable products, which ensure a stream of repeat business as healthcare providers replenish their supplies. Together, these divisions enable Cooper Companies to not only secure a robust market position but also continuously explore new areas for growth and expansion within the broader healthcare industry.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Mar 5, 2026
AI Summary
Q1 2026

Revenue: Consolidated Q1 revenue $1.024 billion, up 6.2% year-over-year (up 2.9% organically); CooperVision $695 million, CooperSurgical $329 million.

Profitability: Q1 gross margin 68.1% and non-GAAP EPS $1.10 (up 20%); operating income improved and operating margin reached 26.9%.

Cash & capital: Q1 free cash flow $159 million with CapEx $102 million; repurchased $92 million of stock and reduced net debt to $2.4 billion.

Guide raise: Management raised EPS guidance to $4.58–$4.66 and increased fiscal 2026 free cash flow guide to $600–$625 million; revenue guidance largely unchanged at $4.30–$4.35 billion.

Demand trends: MyDay portfolio and MiSight drove strength (MiSight +23%); Americas and EMEA showing momentum, Asia Pac pressured by Japan legacy hydrogel decline but expected to recover by fiscal Q3.

Operational actions: Reorganization and IT/AI investments are delivering durable cost synergies; management is reinvesting some savings into sales/marketing and product launches.

Strategic review: Board-led strategic review is ongoing; no definitive update provided but management continues normal operations (buybacks, debt paydown, reinvestment).

Key Financials
Revenue
$1.024 billion
Revenue - CooperVision
$695 million
Revenue - CooperSurgical
$329 million
Organic revenue growth (consolidated)
up 2.9%
Gross margin
68.1%
Operating margin
26.9%
EPS
$1.10
Free cash flow (Q1)
$159 million
CapEx (Q1)
$102 million
Interest expense (Q1)
$22.4 million
Effective tax rate (Q1)
15.1%
Shares outstanding (average)
roughly 197 million
Net debt
$2.4 billion
Share repurchases (Q1)
$92 million (1.1 million shares)
Term loan amendment
$950 million extended to February 2031; $550 million to be repaid December 2026
MiSight performance
grew 23% to [ 28 million ]
PARAGARD
declined 7% in Q1
Tariffs estimate
$24 million
Calendar CooperVision growth (comps)
calendar Q4 grew 10%; full calendar 2025 CooperVision growth 6% vs market 5%
Earnings Call Recording
Other Earnings Calls

Management

Mr. Albert G. White III
President, CEO & Non-Independent Director
No Bio Available
Mr. Brian G. Andrews
Executive VP, CFO & Treasurer
No Bio Available
Mr. Daniel G. McBride Esq.
Executive VP & COO
No Bio Available
Ms. Holly R. Sheffield
President of CooperSurgical, Inc.
No Bio Available
Mr. Gerard H. Warner III
President of CooperVision, Inc.
No Bio Available
Mr. Agostino Ricupati
Senior VP & Chief Accounting Officer
No Bio Available
Mr. Kim Duncan
Vice President of Investor Relations & Risk Management
No Bio Available
Mr. Nicholas S. Khadder
General Counsel & Corporate Secretary
No Bio Available

Contacts

Address
CALIFORNIA
San Ramon
6101 Bollinger Canyon Rd Ste 500
Contacts
+19254603600.0
www.coopercos.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett